ProCE Banner Activity

Managing Key Toxicities With HER2-Targeted Therapies for Breast Cancer

Clinical Thought

Learn how APPs can improve patient outcomes while on HER2-targeted therapies for breast cancer by managing several key toxicities: diarrhea, hepatotoxicity, cardiotoxicity, and interstitial lung disease.

Released: May 31, 2023

Share

Faculty

Jeremy M. Force

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Seagen

Seagen

Disclosure

Primary Author

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Jeremy Force, DO: consultant/advisor/speaker: Exact Science, G1 Therapeutics, Onclive, PRIME.